Abstract
Malignant hyperthermia (MH) is a pharmacogenetic skeletal muscle disease expressed as a hypermetabolic response to volatile anesthetics and/or the depolarizing muscle relaxant succinylcholine and, rarely, to intense physical exercise and ambient heat. Genes linked to the excitation-muscle contraction process are involved, especially the ryanodine receptor 1 gene RYR1. In genetically susce…